ANP (Atrial Natriuretic Peptide) vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | Cagrilintide |
|---|---|---|
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |